



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/331564/2012

European Medicines Agency decision P/0090/2012

of 29 May 2012

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ixekizumab (EMEA-001050-PIP01-10) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0090/2012

of 29 May 2012

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ixekizumab (EMA-001050-PIP01-10) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Eli Lilly & Company Limited on 8 October 2010 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 13 April 2012, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for ixekizumab, solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for ixekizumab, solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 3

A waiver for ixekizumab, solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 4

This decision is addressed to Eli Lilly & Company Limited, Research Center Erl Wood Manor, Sunninghill Road Surrey, GU206PH Windlesham, Surrey, United Kingdom.

Done at London, 29 May 2012

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/207555/2012

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-001050-PIP01-10

Scope of the application

Active substance(s):

Ixekizumab

Condition(s):

Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylarthritis and juvenile idiopathic arthritis)

Treatment of psoriasis vulgaris

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

Eli Lilly & Company Limited



Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Eli Lilly & Company Limited submitted for agreement to the European Medicines Agency on 8 October 2010 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 18 November 2010.

Supplementary information was provided by the applicant on 23 January 2012.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 18 of said Regulation,
- to grant a deferral in accordance with Article 21 of said Regulation,
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Articles 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified subset(s) of the paediatric population and Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex(es) and appendix.

London, 13 April 2012

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition: Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylarthritis and juvenile idiopathic arthritis)

The waiver applies to:

- Children from birth to less than 1 year of age;
- for solution for injection, subcutaneous use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

1.2. Condition: Treatment of psoriasis vulgaris

The waiver applies to:

- The paediatric population from birth to less than 6 years of age;
- for solution for injection, for subcutaneous use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric Investigation Plan

2.1. Condition: Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylarthritis and juvenile idiopathic arthritis)

2.1.1. Indication(s) targeted by the PIP

Treatment of JIA (including polyarticular arthritis, extended oligoarticular arthritis, sJIA without active systemic features, and ERA including JoAS and JPsA) in paediatric patients from the age of 2 years.

Treatment of sJIA with active systemic features in paediatric patients from the age of 1 year.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 1 to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Solution for injection.

2.1.4. Studies

Area	Number of studies	Description
Quality		Study 1) Development of a vial presentation to accommodate weight-adjusted subcutaneous (SC) injection, enabling dosing for children.
Non-clinical	2	Study 2) Repeat-Dose Fertility Study to investigate the potential effects of Ixekizumab Study 3) PPND Toxicity Study to evaluate development of the F1 offspring, including the immune system, following in utero exposure to Ixekizumab
Clinical	2	Study 4) Multicentre, double-blind, randomized, placebo-controlled, safety, tolerability, pharmacokinetic and efficacy study of subcutaneous Ixekizumab in children with juvenile idiopathic arthritis Study 5) Multicentre, double-blind, randomized, placebo-controlled, safety, tolerability, PK, and efficacy study of Ixekizumab in children with systemic juvenile idiopathic arthritis with active systemic features (sJIA).

2.2. Condition: Treatment of psoriasis vulgaris

2.2.1. Indication(s) targeted by the PIP

Treatment of plaque psoriasis

2.2.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 to less than 18 years of age.

2.2.3. Pharmaceutical form(s)

Solution for injection.

2.2.4. Studies

Area	Number of studies	Description
Quality		Study 1) As per condition 2.1
Non-clinical	2	Study 2) As per condition 2.1 Study 3) As per condition 2.1
Clinical	1	Study 6) Multicentre, double-blind, randomized, active- and placebo-controlled study to evaluate safety, tolerability, and efficacy of Ixekizumab in patients from 6 to less than 18 years of age with plaque psoriasis

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By October 2025
Deferral for one or more studies contained in the paediatric investigation plan:	Yes